TransMedics Group Misses Q1 Earnings by $0.32, Stock Slides
NEW YORK, May 6 —
TransMedics Group posted $0.30 in adjusted EPS for Q1 2026, missing consensus by $0.32, with revenue also falling short in the same quarter.
- Adjusted EPS of $0.30 missed analyst consensus by $0.32, implying the street was modeling roughly $0.62 — more than double what the company delivered
- Shares trade at $94.93 on 25.8x forward earnings against $605mn TTM revenue, a multiple that requires accelerating growth and cannot absorb another miss of this size
- Q2 2026 revenue guidance and OCS unit placements or utilization trends from the earnings call are the next hard data points
What Actually Happened
The math is the story. Analysts were modeling roughly $0.62 in adjusted EPS. TransMedics delivered $0.30 — barely half. That is not a rounding error you explain away on a conference call. A miss that size on a $605mn TTM revenue base means either costs ran well above plan or OCS procedure volumes grew slower than analysts projected. The revenue miss makes the second explanation more likely. When both lines disappoint in the same quarter, you cannot pin it on a single accounting item. Something fundamental in the business ran slower than every model assumed.
The Catch
At $94.93 the stock still carries a 25.8x forward multiple. That number was set before this print. If forward estimates come down — and a $0.32 EPS miss is exactly the kind of event that triggers downward revisions — the stock reprices on the lower number before the next quarter even reports. High-multiple med-tech names do not drift down slowly after a double miss. They gap. TransMedics now needs the Q2 call to deliver a specific explanation, not a general one.
Bottom Line
This is less interesting for growth investors after the print, not more. A miss this large needs a specific, credible explanation: a timing issue, a lumpy contract quarter, a cost item that does not repeat. Without one, 25.8x is hard to defend. The single number to watch is Q2 OCS utilization guidance. If adoption is genuinely inflecting, Q1 gets written off as noise. If it is flat, $94.93 is not the floor.
Run a full TransMedics Group analysis, including valuation and growth metrics, at basisreport.com/stock/tmdx.
Basis Report does not hold positions in securities discussed. This is not investment advice.